{"id":381626,"date":"2020-11-16T08:03:36","date_gmt":"2020-11-16T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381626"},"modified":"2020-11-16T08:03:36","modified_gmt":"2020-11-16T13:03:36","slug":"kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/","title":{"rendered":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PRINCETON, N.J., , Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced that Thijs Spoor, Chief Executive Officer, will participate in the following upcoming virtual investor conferences:<\/p>\n<p>\n        <strong>Stifel 2020 Virtual Healthcare Conference<\/strong><br \/>\n        <br \/>Wednesday, November 18, 2020<br \/>Presentation time: 1:20 p.m. EST<\/p>\n<p>\n        <strong>Piper<\/strong><br \/>\n        <strong> Sandler <\/strong><br \/>\n        <strong>32nd Annual Healthcare Conference <\/strong><br \/>\n        <br \/>Monday, November 30 \u2013 Thursday, December 3, 2020<\/p>\n<p>A live audio webcast of Stifel presentation can be accessed through the Presentations section of KBP&#8217;s investor relations website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iWIbUDqdk680udS9zWCCNElF8TMHvICp8xIqnY1wO18PlNpta6sthqCODngbeB8l0VQhtV7suww_mdAESpJPpbhQjYywFFplY1XI-nRNO8c=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>. An archived replay of the webcast will be available on the Company&#8217;s website for 90 days following the live presentation. Mr. Spoor\u2019s presentation at the Piper Sandler conference will be available on-demand via the conference portal and through the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=05M7brOyiP1KZZ63_k8nGUbapWPfzs_ONqOoqEawxcvZ9lJOl4tzVi6p2E-rlO02BmJYl3ibJd8sDDc0dAEDJ6LXzmQDq0dQe-_4Goq0U4YlITnSxPMEFkUH7NjR8H98\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Presentations<\/a> section of the Company\u2019s investor relations website beginning November 23, 2020.<\/p>\n<p>In addition to the presentations, KBP management will be holding 1-on-1 meetings with investors. Investors attending these conferences who are interested in meeting with KBP management should contact their Stifel or Piper Sandler sales representative, or Lee Roth of Burns McClellan at lroth@burnsmc.com, to request a meeting.<\/p>\n<p>\n        <strong>About KBP Bio<\/strong><br \/>\n        <strong>s<\/strong><br \/>\n        <strong>ciences<\/strong><br \/>\n        <br \/>KBP Biosciences is a global, clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations. Headquartered in Princeton, NJ, KBP Biosciences has strong capabilities from discovery and CMC through to global clinical development and registration. KBP Biosciences seeks to develop medicines in its principal therapeutic areas of organ protection and infectious diseases by focusing on novel drug candidates with well-established mechanisms of action.<\/p>\n<p>KBP Biosciences\u2019 lead program, KBP-5074, a novel, non-steroidal MRA, is currently completing a Phase 2b clinical study of Stage 3b\/4 advanced CKD patients with uncontrolled hypertension. KBP Biosciences is also developing KBP-7072, a potent, third-generation tetracycline, a class of antibiotics with established broad anti-infective activity against both Gram-positive and Gram-negative bacteria as well as challenging, atypical pathogens.<\/p>\n<p>KBP Biosciences has built a proprietary R&amp;D platform, which includes a compound library that is the basis of new compound discovery, a bacterium library aimed at multi-drug resistant bacteria, and an in vivo pharmacology platform for screening and testing new compounds. KBP Biosciences is actively seeking to identify additional promising therapeutic opportunities and further develop its product portfolio.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Tyler Ehler<br \/>Investor Relations<br \/>tyler.ehler@kbpbiosciences.com <br \/>+1 (929) 288-9573<\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Lee Roth<br \/>Burns McClellan<br \/>lroth@burnsmc.com<br \/>+1 (212) 213-0006<\/p>\n<p align=\"justify\">\n        <strong>Media: <\/strong><br \/>\n        <br \/>Ryo Imai \/ Robert Flamm, Ph.D.<br \/>Burns McClellan<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zBrS5p_0cpR9cLcvYOeRo-0yFUd2f8w_9J5RgU6XCo21GH8aFrWQPvj1o9UioG9vVuIym0H42ExyHOROQz7n6g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rimai@burnsmc.com<\/a> \/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hYsmDjSdWx-UkdRSnL8v3dkHomQtlB9JTf84S5TX6xDPjUtVVqL6r3XPkUP9Xt9aP5Uxe1EbPisIcHon6xk1vpj3figw5OA4vXE8AXJQLBM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rflamm@burnsmc.com<\/a><br \/>+1 (212) 300-8315 \/ +1 (212) 300-8364<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5418a2b8-1117-4016-b8cc-10f6d6f8ec12\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., , Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced that Thijs Spoor, Chief Executive Officer, will participate in the following upcoming virtual investor conferences: Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020Presentation time: 1:20 p.m. EST Piper Sandler 32nd Annual Healthcare Conference Monday, November 30 \u2013 Thursday, December 3, 2020 A live audio webcast of Stifel presentation can be accessed through the Presentations section of KBP&#8217;s investor relations website here. An archived replay of the webcast will be available on the Company&#8217;s website for 90 days following the live presentation. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;KBP Biosciences to Present at Upcoming Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381626","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., , Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced that Thijs Spoor, Chief Executive Officer, will participate in the following upcoming virtual investor conferences: Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020Presentation time: 1:20 p.m. EST Piper Sandler 32nd Annual Healthcare Conference Monday, November 30 \u2013 Thursday, December 3, 2020 A live audio webcast of Stifel presentation can be accessed through the Presentations section of KBP&#8217;s investor relations website here. An archived replay of the webcast will be available on the Company&#8217;s website for 90 days following the live presentation. &hellip; Continue reading &quot;KBP Biosciences to Present at Upcoming Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T13:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KBP Biosciences to Present at Upcoming Virtual Investor Conferences\",\"datePublished\":\"2020-11-16T13:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/\"},\"wordCount\":430,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/\",\"name\":\"KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\",\"datePublished\":\"2020-11-16T13:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KBP Biosciences to Present at Upcoming Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","og_description":"PRINCETON, N.J., , Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; KBP Biosciences (KBP), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative therapeutics for the treatment of major diseases with large underserved patient populations, today announced that Thijs Spoor, Chief Executive Officer, will participate in the following upcoming virtual investor conferences: Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020Presentation time: 1:20 p.m. EST Piper Sandler 32nd Annual Healthcare Conference Monday, November 30 \u2013 Thursday, December 3, 2020 A live audio webcast of Stifel presentation can be accessed through the Presentations section of KBP&#8217;s investor relations website here. An archived replay of the webcast will be available on the Company&#8217;s website for 90 days following the live presentation. &hellip; Continue reading \"KBP Biosciences to Present at Upcoming Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T13:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences","datePublished":"2020-11-16T13:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/"},"wordCount":430,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/","name":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=","datePublished":"2020-11-16T13:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjY5NSMzODI4MjkyIzIxMjQ0NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kbp-biosciences-to-present-at-upcoming-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KBP Biosciences to Present at Upcoming Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381626"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}